4D Molecular Therapeutics, Inc. (FDMT)
D
Pipeline Grade
Financial Position (from SEC Filings)
$72.5M
Cash & Equivalents
$68.1M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$644M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06864988 | 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | PHASE3 | Active Not Recruiting | 480 |
| NCT07064759 | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul... | PHASE3 | Recruiting | 480 |
| NCT04519749 | An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease | PHASE2 | Active Not Recruiting | 18 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.